High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes

van Meijel, Lian A; de Vegt, Femmie; Abbink, Evertine J; Rutters, Femke; Schram, Miranda T; van der Klauw, Melanie M; Wolffenbuttel, Bruce H R; Siegelaar, Sarah; DeVries, J Hans; Sijbrands, Eric J G

Published in:
BMJ Open Diabetes Research & Care

DOI:
10.1136/bmjdc-2019-000935

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 22-04-2021
High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort


ABSTRACT

Objective People with type 2 diabetes on insulin are at risk for hypoglycemia. Recurrent hypoglycemia can cause impaired awareness of hypoglycemia (IAH), and increase the risk for severe hypoglycemia. The aim of this study was to assess the prevalence and determinants of self-reported IAH and severe hypoglycemia in a Dutch nationwide cohort of people with insulin-treated type 2 diabetes.

Research design and methods Observational study of The Dutch Diabetes Pearl, a cohort of people with type 2 diabetes treated in primary, secondary and tertiary diabetes care centers. The presence of IAH and the occurrence of severe hypoglycemia in the past year, defined as an event requiring external help to recover, were assessed using the validated Dutch version of the Clarke questionnaire. In addition, clinical variables were collected including age, diabetes duration, hemoglobin A1c, ethnicity and education.

Results 2350 people with type 2 diabetes were included: 59.1% men, mean age 61.1±10.4 years, diabetes duration 14.8±9.2 years and 79.5% had a history of severe hypoglycemia in the past year. Almost 10% of patients with type 2 diabetes on insulin therapy was classified as having IAH and 742 patients (31.6%) reported severe hypoglycemia.

Conclusions In this nationwide cohort, almost one out of ten people with type 2 diabetes on insulin had IAH and >30% had a history of severe hypoglycemia in the past year.

Significance of this study

What is already known about this subject?
- Use of insulin therapy in patients with type 2 diabetes creates a risk of developing (severe) hypoglycemia.
- Recurrent (severe) hypoglycemia may lead to the development of impaired awareness of hypoglycemia (IAH).
- The prevalence of IAH in patients with type 1 diabetes is around 25%; however, less is known about the prevalence of IAH in people with type 2 diabetes.

What are the new findings?
- In this nationwide cohort, the prevalence of IAH in patients with type 2 diabetes on insulin therapy was almost 10%.
- The prevalence of severe hypoglycemia in this cohort was more than 30%.
- IAH and severe hypoglycemia occur in patients irrespective of whether they are managed in primary care or not.

How might these results change the focus of research or clinical practice?
- Greater awareness for IAH and severe hypoglycemia in people with type 2 diabetes on insulin is needed.
- Appropriate education to reduce the risk of hypoglycemia in these patients seems warranted.

INTRODUCTION

Insulin-related hypoglycemia is a common adverse effect of insulin therapy. Recent data show almost 98,000 visits to the emergency department and 30,000 hospitalizations in the USA per year due to insulin-related hypoglycemia. Over 75% of these emergency department visits occur in middle-aged or elderly people, suggesting that most of these people suffer from type 2 diabetes.

The reported prevalence of hypoglycemic events in people with type 2 diabetes on insulin therapy is highly variable and partly determined by the duration and intensity of
insulin therapy. Previous studies have shown that people with type 2 diabetes treated with insulin for <2 years experience on average four non-severe episodes per person-year, whereas those treated for >5 years experience 10 episodes per person-year.\(^2\)\(^5\) Similarly, severe hypoglycemia, defined as an event requiring external help to recover, rarely occurs in the first years after the start of insulin therapy but becomes more common during later years.\(^4\)\(^5\) One report estimated the overall prevalence of severe hypoglycemia in type 2 diabetes treated with insulin in secondary care at 0.28 episodes per patient per year.\(^6\)

Recurrent exposure to hypoglycemia can induce a process of habituation leading to impaired awareness of hypoglycemia (IAH). This syndrome increases the risk for developing severe hypoglycemia considerably,\(^5\)\(^6\) yet reflects a functional defect that can be reversed by strict avoidance of hypoglycemia.\(^7\)\(^8\) IAH has been well described in type 1 diabetes and affects approximately 25% of people with type 1 diabetes, a percentage that appears relatively stable across different cohorts and over time.\(^9\)\(^10\)\(^11\) Less information is available concerning the prevalence of IAH in type 2 diabetes, with reported prevalence of IAH in type 2 diabetes treated with insulin in secondary care at 0.28 episodes per patient per year.\(^6\)

The primary outcome of this study was the prevalence of IAH in people with type 2 diabetes on insulin therapy. All participants were therefore asked to complete the clamp-validated Dutch modified translation of the Clarke questionnaire.\(^12\)\(^13\) This questionnaire consists of a validated translation of the original five questions; two questions on symptoms of hypoglycemia, one on the ability to recognize hypoglycemia based on symptoms, one on the level of blood glucose when experiencing hypoglycemic symptoms, and two questions on the occurrence of severe hypoglycemia, one relating to the requirement of a third party, one relating to the need for medical assistance, both in the past year. Each question was awarded with one or zero points, with three or more out of five points indicating IAH. Severe hypoglycemia was defined by a positive answer to one of both questions regarding severe hypoglycemia. Missing data on the Clarke questionnaire were imputed with 0 (having no symptoms) if patients filled in at least one answer.

**Other measurements**

We also assessed a range of demographic and clinical factors including age, diabetes duration, hemoglobin A1c (HbA\(_1c\)), ethnicity, smoking, alcohol consumption, having a partner and level of education, to identify potential risk factors, as described below.

Hospital information systems at all recruitment centers were used to collect information on date of birth and gender. Ethnicity was estimated as described earlier.\(^14\) Education level was self-reported. A high educational level was defined as higher professional education or area or the region of Maastricht) or in secondary and tertiary care in seven of the total eight academic medical centers across the country. Details on the design of the Dutch Diabetes Pearl have been published previously.\(^15\)

The study was approved by Institutional Review Boards of all the participating medical centers. Patients were excluded if they were unable to understand and write the Dutch language.

**Study population**

Patients were enrolled in the Dutch Diabetes Pearl cohort between 2009 and 2015.\(^16\) For this analysis, we only included patients with type 2 diabetes who were treated with insulin. We excluded patients that did not fill in the Clarke questionnaire, including all participants from one center that did not administer this questionnaire (figure 1).

**Study procedure**

After signing informed consent, data were collected following standard operational procedures. Briefly, we collected the following data in the Diabetes Pearl: demographics, physical examinations, laboratory measurements and several questionnaires including the validated Dutch version of the Clarke questionnaire (see below for details).\(^16\)

| Study design | The Dutch Diabetes Pearl is an observational cohort study of people with type 2 diabetes in the Netherlands. The participants are managed in primary care (in the Hoorn area or the region of Maastricht) or in secondary and tertiary care in seven of the total eight academic medical centers across the country. Details on the design of the Dutch Diabetes Pearl have been published previously.\(^15\) The study was approved by Institutional Review Boards of all the participating medical centers. Patients were excluded if they were unable to understand and write the Dutch language. |
| Study outcomes | The primary outcome of this study was the prevalence of IAH in people with type 2 diabetes on insulin therapy. All participants were therefore asked to complete the clamp-validated Dutch modified translation of the Clarke questionnaire.\(^12\)\(^13\) This questionnaire consists of a validated translation of the original five questions; two questions on symptoms of hypoglycemia, one on the ability to recognize hypoglycemia based on symptoms, one on the level of blood glucose when experiencing hypoglycemic symptoms, and two questions on the occurrence of severe hypoglycemia, one relating to the requirement of a third party, one relating to the need for medical assistance, both in the past year. Each question was awarded with one or zero points, with three or more out of five points indicating IAH. Severe hypoglycemia was defined by a positive answer to one of both questions regarding severe hypoglycemia. Missing data on the Clarke questionnaire were imputed with 0 (having no symptoms) if patients filled in at least one answer. |
| Other measurements | We also assessed a range of demographic and clinical factors including age, diabetes duration, hemoglobin A1c (HbA\(_1c\)), ethnicity, smoking, alcohol consumption, having a partner and level of education, to identify potential risk factors, as described below. Hospital information systems at all recruitment centers were used to collect information on date of birth and gender. Ethnicity was estimated as described earlier.\(^14\) Education level was self-reported. A high educational level was defined as higher professional education or |
Impaired awareness of hypoglycemia

The distribution of the modified Clarke score was highly skewed (online supplementary figure S1), with a total of 229 individuals (9.7%) having a score of ≥3 points, classifying them as having IAH. Clinical characteristics of the individuals with and without IAH are shown in table 1. There were no significant differences in the prevalence of IAH between men and women (10.2 vs 9.1%, p=NS) and between patients managed in primary or secondary/tertiary care (8.2 vs 10.4%, p=NS). Although glycemic control did not differ between individuals with or without IAH, the prevalence of IAH was significantly higher among individuals with tight glycemic control as compared with those with glycemic control that was less tight (p=0.046) (figure 2, top). The presence of IAH was associated with complex insulin regimens, non-Caucasian ethnicity, lower BMI and not having a partner, and inversely with the use of sulfonylureas. After multivariate adjustment, complex insulin regimens, not having a partner and lower BMI were still associated with IAH (table 2). There were no statistical differences between the two groups concerning smoking, alcohol consumption, diabetes duration and use of beta-blockers or psychoactive drugs.

Severe hypoglycemia

Severe hypoglycemia in the past 12 months was reported by 742 patients (31.6%), 193 (8.2%) of whom required medical intervention. The prevalence of severe hypoglycemia was similar across sex, but significantly higher among those with poorer glycemic control (p=0.016) (figure 2, bottom). People with a history of severe hypoglycemia were more often non-Caucasian, had a longer diabetes duration, had a history of cardiovascular events, used psychoactive drugs and reported pronounced polypharmacy (table 1). Furthermore, people with severe hypoglycemia were more likely to use complex insulin regimens and less likely to use sulfonylureas or metformin, and were more often seen in secondary/tertiary care than in primary care centers when compared with people without severe hypoglycemia. However, after multivariate adjustment, the level of care was no longer associated with severe hypoglycemia and the same was true for use of sulfonylureas, pronounced polypharmacy and history of cardiovascular disease (table 3).

CONCLUSIONS

In this nationwide cohort of patients with type 2 diabetes treated with insulin, we found that the prevalence of IAH was 9.7% and that almost one out of three individuals reportedly experienced a severe hypoglycemic event in the preceding year. We observed that people not having a partner, with more complex insulin treatment regimens, use of psychoactive drugs, BMI <30 kg/m² and non-Caucasian descent were more susceptible for IAH or severe hypoglycemia. Interestingly, tight glycemic control

Statistical analysis

Data were analyzed using IBM SPSS statistics V.25. Baseline descriptive analyses were expressed as mean±SD, proportion or median (25th and 75th percentiles). Student’s independent two-sample t-tests and Pearson’s χ² tests were performed to examine differences between groups. We performed logistic regression analyses to examine the association between several demographic and clinical variables and IAH and severe hypoglycemia. The regression model for IAH and severe hypoglycemia were cumulatively adjusted for age, sex, diabetes duration, HbA₁c, and for other variables that were significantly associated with the outcome in the crude analysis. A p value of <0.05 was considered statistically significant.
Table 1  Clinical characteristics of people (n=2350) with or without IAH and severe hypoglycemia

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>IAH (n=229)</th>
<th>No IAH (n=2121)</th>
<th>Severe hypoglycemia (n=742)</th>
<th>No severe hypoglycemia (n=1608)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male)</td>
<td>142 (62.0)</td>
<td>1248 (58.8)</td>
<td>437 (58.9)</td>
<td>953 (59.3)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>59.9±11.0</td>
<td>61.2±10.3</td>
<td>60.8±10.5</td>
<td>61.2±10.3</td>
</tr>
<tr>
<td>Clinical care</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary care</td>
<td>55 (24.0)</td>
<td>614 (28.9)</td>
<td>185 (25.1)*</td>
<td>484 (30.2)</td>
</tr>
<tr>
<td>Secondary/tertiary care</td>
<td>173 (75.5)</td>
<td>1497 (70.6)</td>
<td>551 (74.9)*</td>
<td>1119 (69.8)</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>15.5±9.7</td>
<td>14.7±9.1</td>
<td>15.7±9.4*</td>
<td>14.3±9.0</td>
</tr>
<tr>
<td>HbA_1c (%) (mmol/mol)</td>
<td>7.8±1.4 (61.4±15.3)</td>
<td>7.9±1.3 (62.6±14.7)</td>
<td>8.0±1.4 (63.7±15.5)</td>
<td>7.8±1.3 (62.0±14.4)</td>
</tr>
<tr>
<td>Insulin treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal only</td>
<td>25 (10.9)†</td>
<td>453 (21.4)</td>
<td>106 (14.3)*</td>
<td>372 (23.1)</td>
</tr>
<tr>
<td>Pre-mixed</td>
<td>40 (17.5)</td>
<td>339 (16.0)</td>
<td>122 (16.4)</td>
<td>257 (16.0)</td>
</tr>
<tr>
<td>Basal-bolus</td>
<td>163 (71.2)†</td>
<td>1327 (62.6)</td>
<td>513 (69.1)*</td>
<td>977 (60.8)</td>
</tr>
<tr>
<td>Use of sulfonylureas</td>
<td>12 (5.2)†</td>
<td>240 (11.3)</td>
<td>59 (8.0)*</td>
<td>193 (12.0)</td>
</tr>
<tr>
<td>Use of metformin</td>
<td>128 (55.9)</td>
<td>1324 (62.4)</td>
<td>423 (57.0)*</td>
<td>1029 (64.0)</td>
</tr>
<tr>
<td>Pronounced polypharmacy</td>
<td>73 (31.9)</td>
<td>632 (29.8)</td>
<td>263 (35.4)*</td>
<td>442 (27.5)</td>
</tr>
<tr>
<td>Beta-blocker use</td>
<td>86 (37.6)</td>
<td>859 (40.5)</td>
<td>298 (40.2)</td>
<td>647 (40.2)</td>
</tr>
<tr>
<td>Psychoactive drug use</td>
<td>52 (22.7)</td>
<td>477 (22.5)</td>
<td>209 (28.2)*</td>
<td>320 (19.9)</td>
</tr>
<tr>
<td>Ethnicity (Caucasian)</td>
<td>169 (75.4)†</td>
<td>1714 (81.5)</td>
<td>565 (77.2)*</td>
<td>1318 (82.6)</td>
</tr>
<tr>
<td>Partner (yes)</td>
<td>122 (63.2)†</td>
<td>1301 (73.5)</td>
<td>443 (72.0)</td>
<td>980 (72.7)</td>
</tr>
<tr>
<td>High educational level (yes)</td>
<td>54 (23.8)</td>
<td>499 (23.6)</td>
<td>159 (21.6)</td>
<td>394 (24.6)</td>
</tr>
<tr>
<td>Current smoker (yes)</td>
<td>47 (20.6)</td>
<td>389 (18.4)</td>
<td>145 (19.6)</td>
<td>291 (18.2)</td>
</tr>
<tr>
<td>High alcohol consumption (≥14 glasses/week)</td>
<td>15 (6.6)</td>
<td>132 (6.3)</td>
<td>49 (6.7)</td>
<td>98 (6.2)</td>
</tr>
<tr>
<td>BMI≥30 (kg/m²)</td>
<td>112 (49.3)†</td>
<td>1198 (57.3)</td>
<td>410 (55.8)</td>
<td>900 (56.9)</td>
</tr>
<tr>
<td>History of cardiovascular disease (yes)</td>
<td>81 (35.4)</td>
<td>645 (30.4)</td>
<td>261 (35.2)*</td>
<td>465 (28.9)</td>
</tr>
</tbody>
</table>

Data are shown as number (%) or mean±SD. History of cardiovascular disease was defined as having ≥1 of the following: acute myocardial infarction, cerebrovascular event, transient ischemic attack, peripheral artery disease. Pronounced polypharmacy was defined as using ≥10 drugs.

*p<0.05 versus no SH.
†p<0.05 versus no IAH

BMI, body mass index; IAH, impaired awareness of hypoglycemia; SH, severe hypoglycemia.

was associated with a higher prevalence of IAH, but at the same time with a lower risk of severe hypoglycemia. Furthermore, the prevalence of severe hypoglycemia was significantly higher in secondary/tertiary care, but the association between level of care and severe hypoglycemia was no longer statistically significant after multivariate adjustment.

Our data on the prevalence of IAH in people with insulin-treated type 2 diabetes are in line with those reported in small studies using either the Gold score or the Clarke questionnaire, and extend these to a more general population of people with type 2 diabetes on insulin, including those from primary care. In accordance with previous findings, participants with IAH had somewhat tighter and those with severe hypoglycemia had somewhat poorer metabolic control. Our data contrast with single-center surveys from Denmark and Turkey that reported IAH to vary between 31% and even 94% among people with type 2 diabetes on insulin. Part of this discrepancy may result from differences between questionnaires, thus potentially identifying different subgroups. We used the Dutch modified version of the Clarke questionnaire, which has been validated against hypoglycemic clamps in people with type 1 diabetes.
The methods by Gold and Clarke have a good mutual concordance and good predictability for biochemical hypoglycemia, but correlate less well with the method used in Denmark. The latter method has been criticized for overestimating the prevalence of IAH.

IAH was almost as prevalent in people with type 2 diabetes managed by primary care physicians as in those managed in secondary/tertiary care centers. The prevalence of severe hypoglycemia was slightly higher in secondary/tertiary care when compared with primary care. In fact, the association between type of care and severe hypoglycemia was completely lost after correction for age, sex, diabetes duration and HbA1c. Conversely, use of a complex insulin regimen increased the risk for both IAH and severe hypoglycemia, which was independent of where they received their care. The size and diversity of our cohort enabled us to also uncover non-Caucasian ethnicity and having no partner as independent new determinants of severe hypoglycemia and IAH, respectively, in people with type 2 diabetes, whereas we found no evidence for associations with smoking, as reported previously.

Use of metformin was independently associated with lower odds of severe hypoglycemia in our population, which corroborates findings of a recent large cohort study. The underlying mechanism explaining this observation remains to be determined. Metformin has been shown to modestly enhance the release of growth hormone during hypoglycemia, but not that of other counterregulatory hormones. Alternatively, metformin-induced increases in plasma lactate may preserve brain function during hypoglycemia, thus potentially providing protection against severe hypoglycemia.

In univariate analysis, we also found an inverse relationship between use of sulfonylureas and IAH or severe hypoglycemia. Since particularly long-acting sulfonylureas are associated with increased risks of hypoglycemia, this seemingly paradoxical finding is best explained by reverse causality. Indeed, it is highly likely that sulfonylureas were stopped after intensifying insulin therapy, in accordance with international guidelines, or after experiencing severe or frequent hypoglycemic events, and not even commenced in patients thought to be at increased risk of hypoglycemia.
Our study has clinical implications as it shows that both IAH and severe hypoglycemia are common in people with type 2 diabetes on insulin therapy, even in those using basal insulin therapy alone or managed in primary care. Remarkably, although the prevalence of IAH in type 2 diabetes is at least twofold lower than what has been reported in type 1 diabetes, the occurrence of severe hypoglycemia was at least of the same magnitude. A lack in education about hypoglycemia focused on this population may explain at least a part of this discrepancy. The symptomatology of hypoglycemia may differ in elderly people with type 2 diabetes, whereas those with type 1 diabetes are usually younger, have longer experience with insulin treatment and consequently may already have been educated more intensively and more frequently about hypoglycemia. Some other risk factors for IAH in our study, for example non-Caucasian ethnicity, may also be partly explained by an educational gap. Focused education may reduce the burden of hypoglycemia and its potentially harmful consequences (eg, falls), as well as the associated risk of cardiovascular morbidity and mortality.

Strengths of our study include the size of the cohort, being the largest to date in which the prevalence of IAH in type 2 diabetes has been determined and its national coverage due to the collaboration of all academic medical centers in the Netherlands. The inclusion of primary, secondary and tertiary care patients and the use of standardized protocols for data collection increase its generalizability. Our study also has limitations. Based on selection by academic centers, there may be an over-representation of complicated tertiary care patients. However, it should be noted that most previous studies also collected data in academic centers. Second, the questionnaire we used to estimate IAH has not formally been validated in type 2 diabetes, but this applies to all questionnaires currently used for this purpose. Future research is needed to validate the questionnaire in patients with type 2 diabetes. Finally, we did not measure C-peptide values, the presence of which has been associated with lower hypoglycemia risks in people with type 1 diabetes, and most data were collected before the widespread use of continuous glucose monitoring techniques.

In conclusion, IAH and severe hypoglycemia are relatively common among people with type 2 diabetes treated with insulin, particularly when managed with an intensified regimen, but independent of whether this is applied in primary, secondary or tertiary care. Greater awareness for IAH and severe hypoglycemia in people with type 2 diabetes on insulin is needed, with special attention for people without a partner or with non-Caucasian ethnicities. Appropriate education to reduce the risk of hypoglycemia in people with type 2 diabetes on insulin seems warranted, although this remains to be investigated.

**Author affiliations**

1Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
2Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
3Department of Epidemiology & Biostatistics, Amsterdam UMC - Locatie VUMC, Amsterdam, The Netherlands
4Department of Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands
5Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands
6Department of Internal Medicine, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands
7Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
8Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
9Department of General Practice and Elderly Care, Amsterdam Public Health Research Institute, Amsterdam UMC - Locatie VUMC, Amsterdam, The Netherlands
10Department of General Practice and Elderly Care, Amsterdam Public Health Research Institute, Amsterdam UMC - Locatie VUMC, Amsterdam, The Netherlands

**Acknowledgements** We thank all the volunteers for their participation in the Dutch Diabetes Pearl cohort. We also thank O. Dekkers for his feedback on an earlier draft of the manuscript.

**Contributors** BEDG and CJT designed the study. FdV analyzed the data. LAVM wrote the first draft of the manuscript. LAVM, FdV, EJA, FR, MTS, MMvdK, BHRW,
Epidemiology/Health Services Research

SS, JHD, EJGS, BÖ, HWdV, BS, NS, CDAS, PJE, CJT, BEDG critically revised and contributed to the final version of the manuscript. LAvM, FdV, CJT and BEDG are the guarantors of this work and accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding The initial organization of the Dutch Diabetes Pearl was co-financed by the Dutch Government and the eight Dutch University Medical Centers. The continuation is financed by the Dutch Federation of University Medical Centers. The funding body had no role in designing the study or in collecting, analyzing, or interpreting data, writing of the report or in the decision to submit the article for publication. The research has been conducted fully independent of the funders, and all authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Competing interests FR has received grants from the Dutch government, during the conduct of the study. JHD has received personal fees from Novo Nordisk and Sanofi, outside the submitted work. CJT has received grants from AstraZeneca, personal fees and other from NovoNordisk and from Merck, outside the submitted work. BEDG has received grants from the Dutch Federation of University Medical Centers, during the conduct of the study and personal fees from NovoNordisk, outside the submitted work.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Lian A van Meijel http://orcid.org/0000-0001-6579-8488
Miranda T Schram http://orcid.org/0000-0001-8113-7604
Cornelis J Tack http://orcid.org/0000-0003-0222-1653
Bastiaan E de Galan http://orcid.org/0000-0002-1255-7741

REFERENCES
Epidemiology/Health Services Research